Read by QxMD icon Read

Clinical Colorectal Cancer

Chung Ryul Oh, Jeong Eun Kim, Jihoon Kang, Sun Young Kim, Kyu-Pyo Kim, Yong Sang Hong, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim, Jihun Kim, Se Jin Jang, Tae Won Kim
BACKGROUND: We investigated whether the microsatellite instability (MSI) status affects the survival outcomes in patients with stage II/III rectal cancer who have undergone an upfront curative resection. PATIENTS AND METHODS: A total of 1103 patients with curatively resected stage II/III rectal cancer who had available polymerase chain reaction-based MSI results were included in the final analysis. RESULTS: Twenty-four (2.2%) patients in the total cohort were found to be MSI-high (MSI-H)...
July 9, 2018: Clinical Colorectal Cancer
Sumana Narayanan, Emmanuel Gabriel, Kristopher Attwood, Patrick Boland, Steven Nurkin
BACKGROUND: Previous studies have shown that variability in molecular markers correlates with poorer survival outcomes in patients with right-sided colon cancer (RCC) compared with left-sided colon cancer (LCC). However, several studies have shown conflicting results when examined stage for stage. We examined RCC and LCC to assess for differences in histopathologic features and overall survival (OS). MATERIALS AND METHODS: The National Cancer Database was used to identify patients with RCC and LCC from 2004 to 2013...
July 5, 2018: Clinical Colorectal Cancer
Laura Rodriguez, Kelly Brennan, Safiya Karim, Sulaiman Nanji, Sunil V Patel, Christopher M Booth
INTRODUCTION: The incidence of colorectal cancer in young patients has been increasing. We evaluated whether the disease characteristics, management, and outcomes of patients with colon cancer differ among patients aged ≤ 40 years compared with those of older patients. MATERIALS AND METHODS: Using the Ontario Cancer Registry, all cases of colon cancer (stage I, II, III) treated with surgery in Ontario from 2002 to 2008 were identified. The electronic medical records of treatment were used to identify the use of surgery and adjuvant chemotherapy (ACT)...
July 3, 2018: Clinical Colorectal Cancer
Aixa E Soyano, Candice Baldeo, Pashtoon M Kasi
No abstract text is available yet for this article.
July 3, 2018: Clinical Colorectal Cancer
Jun Woo Bong, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Tae Won Kim, Jin Cheon Kim
BACKGROUND: Bevacizumab (BV) has been approved for treating colorectal cancer since 2004. Although BV use may lead to adverse effects, few studies have reported incidences requiring surgical intervention. We aimed to identify the risk factors and adequate interventions for complications requiring surgical intervention after BV treatment. PATIENTS AND METHODS: We retrospectively reviewed the records of patients with metastatic colorectal cancer treated with BV in our institute from January 2009 to December 2016...
June 28, 2018: Clinical Colorectal Cancer
James J Lee, Edward Chu
Metastatic colorectal cancer (mCRC) continues to be associated with a poor prognosis, and there remains a significant unmet need for novel agents and treatment regimens. Major breakthroughs have been made with immune checkpoint blockade therapy in several disease types, including DNA mismatch repair deficient/microsatellite instability-high (MSI-H) tumors. To date, however, immune checkpoint monotherapy has not shown significant clinical activity in the treatment of patients with mismatch repair proficient (pMMR)/non-MSI-H mCRC...
June 21, 2018: Clinical Colorectal Cancer
George Pentheroudakis, Vassiliki Kotoula, Georgia-Angeliki Koliou, Vasilios Karavasilis, Epaminontas Samantas, Gerasimos Aravantinos, Lydia Kalogeropoulou, Ioannis Souglakos, Nikolaos Kentepozidis, Georgios Koumakis, Joseph Sgouros, Georgios Zarkavelis, Ioannis Efstratiou, Konstantinos Laschos, Constantina Petraki, Ioannis Tikas, Christos Poulios, Alexandra Voutsina, Athina Goudopoulou, Dimitrios Bafaloukos, Eleni Vrettou, Anna Kalogera-Fountzila, Dimitrios Pectasides, George Fountzilas
BACKGROUND: The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: In the context of a prospective single-arm trial (NCT02129257), patients with mCRC received standard doses of a maximum of 12 cycles of FOLFIRI combined with aflibercept (4 mg/kg body weight delivered intravenously) every 2 weeks, followed by aflibercept maintenance...
June 15, 2018: Clinical Colorectal Cancer
Peter Gibbs, Volker Heinemann, Navesh K Sharma, Julien Taieb, Jens Ricke, Marc Peeters, Michael Findlay, Bridget Robinson, Christopher Jackson, Andrew Strickland, Val Gebski, Mark Van Buskirk, Huaqing Zhao, Guy van Hazel
BACKGROUND: The primary tumor side is emerging as a major prognostic factor for patients with metastatic colorectal cancer (mCRC). We examined the survival data from 2 randomized studies to determine whether the outcomes differ between patients with mCRC with right-sided primary (RSP) tumors and those with left-sided primary (LSP) tumors after selective internal radiation therapy (SIRT) plus mFOLFOX6 (folinic acid [leucovorin], 5-fluorouracil, oxaliplatin) chemotherapy, versus chemotherapy alone...
June 12, 2018: Clinical Colorectal Cancer
Matthias Unseld, Magdalena Drimmel, Alexander Siebenhüner, Andreas Gleiss, Daniela Bianconi, Markus Kieler, Werner Scheithauer, Thomas Winder, Gerald W Prager
BACKGROUND: Treatment sequencing for patients with refractory metastatic colorectal cancer (mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib have demonstrated clinical benefits in randomized phase III trials compared with placebo. However, limited data are available on the most optimal therapy sequence involving TAS-102 and regorafenib. PATIENTS AND METHODS: In the present retrospective, observational, real-life study, clinical data on mCRC patients treated with TAS-102 or an alternative salvage treatment at the Medical University of Vienna and University Hospital Zurich were collected from January 2013 to December 2016...
June 8, 2018: Clinical Colorectal Cancer
Raghav Sundar, Susana Miranda, Daniel Nava Rodrigues, Maxime Chénard-Poirier, David Dolling, Matthew Clarke, Ines Figueiredo, Claudia Bertan, Wei Yuan, Ana Ferreira, Rossitza Chistova, Gunther Boysen, Desamparados Roda Perez, Nina Tunariu, Joaquin Mateo, Andrew Wotherspoon, Ian Chau, David Cunningham, Nicola Valeri, Suzanne Carreira, Johann de Bono
BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein expression in colorectal cancer and correlated this with clinical outcomes. MATERIALS AND METHODS: The clinical outcomes data and tumor samples from metastatic colorectal cancer patients referred to the Royal Marsden Hospital Drug Development Unit (United Kingdom) from 2012 to 2016 and providing consent for a molecular characterization study were analyzed...
June 8, 2018: Clinical Colorectal Cancer
Michael Davidson, Catherine Cafferkey, Emily Frances Goode, Kyriakos Kouvelakis, Daniel Hughes, Pablo Reguera, Eleftheria Kalaitzaki, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling
BACKGROUND: Although progress has been made in the molecular stratification of esophagogastric adenocarcinoma, the outlook for advanced disease remains poor. The present evaluation of over 500 patients treated at a single European high-volume tertiary center during a 6-year period gives important information on current and developing "real-world" treatment patterns and outcomes. RESULTS: The overall survival for the whole cohort was 11.5 months, with a range of treatments used in first-, second-, and third-line settings...
June 8, 2018: Clinical Colorectal Cancer
Matthew Burge, Christine Semira, Belinda Lee, Margaret Lee, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Brigette Ma, Andrew P Dean, Allan S Zimet, Simone A Steel, Sheau Wen Lok, Javier Torres, Melissa Eastgate, Hui-Li Wong, Peter Gibbs
BACKGROUND: The FIRE-3 [5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment colorectal cancer (CRC)] study reported that first-line FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab resulted in similar progression-free survival (PFS) but improved overall survival (OS). A potential explanation is that the initial biologic agent administered in metastatic CRC (mCRC) affects later line efficacy of the other treatments...
June 1, 2018: Clinical Colorectal Cancer
Kazushige Kawai, Eiji Sunami, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Kensuke Otani, Kazuhito Sasaki, Hiroaki Nozawa
INTRODUCTION: Chemoradiotherapy (CRT) is the standard treatment for locally advanced rectal cancer; however, the optimal chemotherapy sequence to administer simultaneously with radiotherapy remains unclear. We conducted a phase I/II study to test a new regimen, TEGAFIRI (combination tegafur, uracil [UFT], leucovorin [LV], irinotecan), for patients with locally advanced rectal cancer. PATIENTS AND METHODS: A total of 22 patients with locally advanced lower rectal adenocarcinoma were enrolled in the present study...
June 1, 2018: Clinical Colorectal Cancer
Daniel Brungs, Morteza Aghmesheh, Paul de Souza, Martin Carolan, Philip Clingan, June Rose, Marie Ranson
BACKGROUND: Colon cancer is common in the elderly, but owing to under representation in clinical trials, the benefit of standard therapies is uncertain in this age group. We aimed to clarify the efficacy and complications of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for patients 70 years and older with stage III colon cancer. PATIENTS AND METHODS: All patients with stage III colon adenocarcinoma were identified from an Australian cancer registry (2006-2013)...
May 31, 2018: Clinical Colorectal Cancer
Margaret M Lee, Andrew MacKinlay, Christine Semira, Christine Schieber, Antonio Jose Jimeno Yepes, Belinda Lee, Rachel Wong, Chathurika K H Hettiarachchige, Natalie Gunn, Jeanne Tie, Hui-Li Wong, Iain Skinner, Ian T Jones, James Keck, Suzanne Kosmider, Ben Tran, Kathryn Field, Peter Gibbs
BACKGROUND: Multiple studies have defined the prognostic and potential predictive significance of the primary tumor side in metastatic colorectal cancer (CRC). However, the currently available data for early-stage disease are limited and inconsistent. MATERIALS AND METHODS: We explored the clinicopathologic, treatment, and outcome data from a multisite Australian CRC registry from 2003 to 2016. Tumors at and distal to the splenic flexure were considered a left primary (LP)...
May 26, 2018: Clinical Colorectal Cancer
Fangying Xu, Si Li, Jing Zhang, Lili Wang, Xuesong Wu, Jing Wang, Qiong Huang, Maode Lai
BACKGROUND: Tumor tissues consist of heterogeneous cancer cells and stroma cells, including cancer stem cells and immune cells. Epithelial-mesenchymal transition (EMT) programs closely associate with acquisition of stemness. We investigated for the first time the clinical significance of combining cancer stem cells, immune cells, and EMT traits. MATERIALS AND METHODS: In 419 colorectal carcinomas, stem-cell markers (Nanog, Lgr5, CD44v6, ALDH1A1), EMT markers (E-cadherin, Snail), and immune-cell markers (CD3+ , CD4+ or CD8+ T lymphocytes, CD20+ B lymphocytes, CD68+ macrophages) were detected in tumor center (TC) and tumor invasive front by an immunohistochemical method...
May 26, 2018: Clinical Colorectal Cancer
Bartosz Mucha, Dariusz Pytel, Lukasz Markiewicz, Magda Cuchra, Izabela Szymczak, Karolina Przybylowska-Sygut, Adam Dziki, Ireneusz Majsterek, Lukasz Dziki
BACKGROUND: Colorectal cancer (CRC) is leading malignant tumors to occur mainly in industrialized countries, where it exhibits one of the highest mortality rates. Up to 80% of all CRCs characterize a chromosomal instability (CIN) phenotype. The main challenge faced by scientist is to reveal the mechanism of CIN development. An often proposed model is defects in DNA repair in terms of efficiency and genetic variations that modulate the response to stimuli from the environment. The objectives of this research were to determine whether nucleotide excision repair (NER) might affect CRC risk...
June 2018: Clinical Colorectal Cancer
Mai-Britt Worm Ørntoft
Colorectal cancer (CRC) is a leading cause of cancer related deaths worldwide, and late stages (III-IV) in particular have low 5-year survival rates. Stage shifting by CRC screening programs has proven effective by decreasing morbidity and mortality and in many countries national CRC screening programs have been implemented. Currently, European, Asian, and American authorities recommend screening for CRC using fecal occult blood testing, sigmoidoscopy, or colonoscopy. Because these approaches all have weaknesses (eg, poor compliance, high costs, test invasiveness), much effort has been put into the development of alternative screening approaches, many of which are blood-based...
June 2018: Clinical Colorectal Cancer
Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Chiara Cremolini, Carlotta Antoniotti, Beatrice Borelli, Tetsuo Mashima, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Roel Gopez, Afsaneh Barzi, Sara Lonardi, Toshiharu Yamaguchi, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz
BACKGROUND: The C-C motif chemokine ligand 5/C-C motif chemokine receptor 5 (CCL5/CCR5) pathway has been shown to induce endothelial progenitor cell migration, resulting in increased vascular endothelial growth factor A expression. We hypothesized that genetic polymorphisms in the CCL5/CCR5 pathway predict efficacy and toxicity in patients with metastatic colorectal cancer (mCRC) treated with regorafenib. PATIENTS AND METHODS: We analyzed genomic DNA extracted from 229 tumor samples from 2 different cohorts of patients who received regorafenib: an evaluation cohort of 79 Japanese patients and a validation cohort of 150 Italian patients...
June 2018: Clinical Colorectal Cancer
Nele Boeckx, Ken Op de Beeck, Matthias Beyens, Vanessa Deschoolmeester, Christophe Hermans, Peggy De Clercq, Sonia Garrigou, Corinne Normand, Els Monsaert, Konstantinos Papadimitriou, Pierre Laurent-Puig, Patrick Pauwels, Guy Van Camp, Valerie Taly, Marc Peeters
BACKGROUND: Targeted therapies, although contributing to survival improvement in metastatic colorectal cancer (mCRC), are expensive and may cause adverse effects. Therefore, confirming that patients are responding to these therapies is extremely important. Currently, follow-up is performed using radiographic evaluation, which has its limitations. Liquid biopsies, reflecting real-time tumor characteristics, hold great potential in monitoring tumor disease. PATIENTS AND METHODS: Blood samples were collected at different time points during treatment of 24 mCRC patients...
June 2018: Clinical Colorectal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"